CommercialCoverageMedium impact
08.01.21h, Blinatumomab (Blincyto®)
Independence Blue Cross·Oncology, Hematology, Pharmacy·Pharmacy
Effective date
Oct 20, 2025
We identified it
Jun 19, 2026
Summary
Independence Blue Cross updated its blinatumomab (Blincyto®) policy to align with current NCCN recommendations for acute lymphoblastic leukemia (ALL) treatment. The policy now reorganizes medical necessity criteria by Philadelphia Chromosome status first, then by minimal residual disease (MRD) status, and adds new treatment regimens for ALL with additional mutations. The policy clarifies that AYA (adolescent and young adult) includes ages 15–39 years, and removes ICD-10 codes (requiring providers to report the most appropriate diagnosis code based on clinical criteria).
Action Required
By October 20, 2025: (1) Billing team must update authorization and claims processing systems to reflect the reorganized medical necessity criteria for blinatumomab (HCPCS J9039), prioritizing Philadelphia Chromosome status determination followed by MRD status assessment. (2) Oncology providers must ensure proper diagnosis code documentation on all blinatumomab claims, as ICD-10 codes are no longer listed in the policy—claims must include the most appropriate diagnosis code supporting medical necessity criteria (e.g., specific ALL type, age group, relapsed/refractory status). (3) Prior authorization reviewers must apply the updated NCCN-aligned criteria for Ph-positive and Ph-negative B-ALL across all age groups (infants, pediatric, AYA ages 15–39, and adults). (4) Update internal billing guidelines and prior auth templates to reflect expanded treatment regimens for ALL with additional mutations. Failure to use current criteria may result in claim denials or delays.